Evidence map›Paper›PMID 42723896›Full record

ArticleFrontiers in neurology2026

Sustained LDL-C target attainment and recurrent ischemic cerebrovascular events after ischemic stroke: effect modification by large-artery disease.

Xiaofeng Zhang, Di Niu, Yikang Li, Yuanyuan Wang, Ruizhi Chen, Guoping Xing

Abstract read
In one paragraph

Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaofeng ZhangSchool of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Di NiuSchool of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Yikang LiSchool of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Yuanyuan WangDepartment of Neurology, Weifang People's Hospital, Weifang, Shandong, China.
Ruizhi ChenDepartment of Neurology, Weifang People's Hospital, Weifang, Shandong, China.
Guoping XingDepartment of Neurology, Weifang People's Hospital, Weifang, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In secondary prevention after ischemic stroke or TIA, LDL-C < 1.8 mmol/L is associated with a lower risk of recurrent vascular events. However, evidence remains limited in real-world patients with ischemic stroke, especially those with significant large-artery atherosclerotic stenosis. In particular, few studies have evaluated the impact of sustained LDL-C target attainment on recurrent ischemic cerebrovascular events by using LDL-C target attainment as a time-varying exposure. Methods: We retrospectively studied 933 patients with ischemic stroke who had baseline LDL-C levels ≥1.8 mmol/L at admission. Significant large-artery disease (LAD) was defined as ≥50% intracranial or extracranial atherosclerotic stenosis. LDL-C target attainment was defined as <1.8 mmol/L. The primary outcome was recurrent ischemic cerebrovascular events. Time-dependent Cox models evaluated the association between time-varying LDL-C target attainment and recurrence, and effect modification by LAD status was assessed. The proportion of follow-up time with LDL-C ≥ 1.8 mmol/L was additionally assessed. Results: Among 933 patients, 369 had LAD and 564 did not. During follow-up, 102 recurrent ischemic cerebrovascular events occurred. In the fully adjusted model, time-varying LDL-C target attainment was associated with lower recurrence risk [hazard ratio (HR) = 0.399, 95% confidence interval (CI): 0.269-0.593, Conclusion: Among patients with ischemic stroke who had baseline LDL-C levels ≥1.8 mmol/L at admission, sustained LDL-C target attainment was associated with a lower risk of recurrence after ischemic stroke. This association was particularly evident in patients with significant LAD. Sustained LDL-C control may support risk stratification and secondary prevention.

Indexed as

Brain IschemiaCholesterol, LDLIntracranial ArteriosclerosisIschemic StrokeAgedFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesSecondary PreventionCholesterol, LDLischemic strokelarge-artery atherosclerosisLDL-C target attainmentlow-density lipoprotein cholesterolrecurrent cerebrovascular eventstime-dependent Cox regression

Identifiers

PMID42723896
PMCPMC13558011

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.